From the AGM management presentation the Zen3694 trials in most of the 11 indications seem to be trending in a positive direction....  wondering if Zenith is applying for a fast track designation for any of the trials especially the Nut Carcinoma since its dealing with Pediatric patients who's lifespan with the desease is relatively short....